Press Releases

Valicare GmbH, a wholly owned subsidiary of Syntegon,now offers additional services along the entire product life cycle of pharmaceutically and biotechnologically produced drugs. A new focus is on consulting services for the transition of products from the development phase to the GMP compliant manufacturing of investigational medicinal products.These services are complemented by the presentation and assessment of market-specific requirements, investigational drug management and the necessary

The Salk Institute and BridgeBio Pharma, Inc. announced a three-year collaboration agreement formed to advance cutting-edge academic discoveries in genetically driven diseases toward therapeutic applications. Under the partnership, BridgeBio will help fund research programs from Salk’s world-renowned innovative cancer research, with the eventual goal of developing new therapeutics for patients in need. “Salk is known for its outstanding research, in particular in the fie

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, and TScan Therapeutics, Inc., a biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies in oncology,  announced a research collaboration and license agreement to explore developing TCR-T cell therapies for the treatment of COVID-19.  Poseida&

The new pharma partnering event concept "Marketplace for Pharma Business Opportunities" allows for physical and virtual one-on-one meetings, not on the same event days, but with a 28-days video meetings period immediately following a 2-days physical event. The new design proved itself in practice under corona conditions in September in Vienna producing more than 70 video business discussions for some attendees. Says Dr. Norbert Rau, Co-founder of Heidelberg, Germany, based

Medical Festival Asia, a 10-day online event for the medical and healthcare sector will take place from the 9 to 18 December 2020. The Festival will include four pillar components, a trade marketplace with an online exhibition –MEDICAL FAIR ASIA 2020 Digital Edition, thought-leadership conferences, an awards ceremony recognising the best healthcare companies, and knowledge-sharing seminars and technical presentations. To be held biennially, Medical Festival Asia is a concept b

InterVenn, a San Francisco based biotechnology company innovating precision medicine and diagnostic products using next-generation mass spectrometry coupled to a proprietary artificial Intelligence/machine learning-based data processing engine, has announced a collaboration with Agilent Technologies, a leading provider of bio-analytical and scientific instrumentation. The signing of the collaboration took place on 7 September 2020, with Mr. Fadzhairi Jabar, InterVenn Malaysia’s General

Cytocom, Inc. (Cytocom), a leading biopharmaceutical company in the area of immune-modulation, and Cleveland BioLabs, Inc., , an innovative biopharmaceutical company developing novel approaches to activate the immune system, today announced that they have entered into a definitive merger agreement to combine their businesses in an all-stock transaction. Cytocom shareholders will have a majority position in the newly combined entity, which the parties anticipate will continue to be listed on t

CPhI Worldwide (31 August – 2 September 2021) will be held next year in Milan (Fiera Milano) for the first time in over a decade – following its postponement in 2020. The event returns at an apt moment, as the pharma industry in Italy is anticipated to be one of the main beneficiaries of geo-diverse sourcing strategies. Italy is Europe’s largest producer and exporter of APIs – 85% are exported to North America, the EU and Japan[1] – and the 2020 CPhI An

ProteoNic BV, a leading provider of technology and services in the field of production of biologics, today announced it has licensed its premium 2G UNic™ technology for boosting therapeutic protein production to Immunomedics, Inc. (NASDAQ: IMMU), a biopharmaceutical company developing immuno-therapeutics for the treatment of cancer and other diseases. Under the agreement, Immunomedics gains commercial rights for application of ProteoNic’s technology platform to the devel

ATMPS Ltd – a spinout of FarmaTrust announces that its Hataali blockchain platform has been successfully tested with University Hospitals Birmingham NHS Foundation Trust’s system interface. Data interoperability was shown to be possible, rendering the Hataali platform as the world’s first blockchain solution for advanced therapeutic medicinal products. Hataali[1] is a new pioneering blockchain-based cell orchestration platform that is interoperable with any other s